ATHA Stock Recent News

ATHA LATEST HEADLINES

ATHA Stock News Image - proactiveinvestors.com

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced that it has entered into option agreement with Terra Uranium Ltd (ASX:T92) which allow the two companies to earn significant interest in each other's uranium exploration projects. ATHA has granted Terra Uranium an option to acquire up to 70% interest in its Spire and Horizon properties, together the Spire Horizon projects.

proactiveinvestors.com 2024 Oct 11
ATHA Stock News Image - proactiveinvestors.com

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) CEO Troy Boisjoli highlighted the company's aggressive growth strategy and plans for the year ahead in a discussion at the TD Securities Annual Nuclear Fuel Cycle and Next Generation Nuclear Roundtable. ATHA, listed in April 2023, has rapidly expanded its uranium exploration portfolio.

proactiveinvestors.com 2024 Oct 10
ATHA Stock News Image - proactiveinvestors.com

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has expanded its Angilak Project in Nunavut by acquiring the entire Lac 50 structural corridor, along with an additional prospective parallel corridor. Both corridors are linked to the Snowbird Tectonic Zone, a significant crustal structure that extends from the Athabasca Basin to the Angikuni Basin.

proactiveinvestors.com 2024 Sep 19
ATHA Stock News Image - geekwire.com

Seattle-based biotech company Athira Pharma is laying off 49 people, or about 70% of its workforce, as part of cost-cutting measures and a restructuring.

geekwire.com 2024 Sep 17
ATHA Stock News Image - zacks.com

Athira's phase II/III LIFT-AD study on fosgonimeton for treating mild-to-moderate Alzheimer's disease fails to meet primary and secondary endpoints.

zacks.com 2024 Sep 04
ATHA Stock News Image - benzinga.com

On Wednesday, Athira Pharma, Inc. ATHA stock is trading lower after the company released topline results from its Phase 2/3 LIFT-AD clinical trial of fosgonimeton for mild-to-moderate Alzheimer's disease (AD).

benzinga.com 2024 Sep 04
ATHA Stock News Image - reuters.com

Athira Pharma said on Tuesday its investigative drug failed to meet the main goal in a mid-to-late stage trial in patients with mild-to-moderate Alzheimer's disease.

reuters.com 2024 Sep 03
ATHA Stock News Image - proactiveinvestors.com

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) announced it has completed its 2024 Exploration Program at its Angilak uranium project in Nunavut, which hosts the Lac 50 uranium Deposit. The “highly successful” program was carried out from early June to late August and involved 25 diamond drill holes totalling about 10,051 meters.

proactiveinvestors.com 2024 Sep 03
ATHA Stock News Image - proactiveinvestors.com

ATHA Energy Corp (CSE:SASK, OTCQB:SASKF) has provided investors with an update on its 2024 exploration programs at its uranium projects. At its Gemini project in the Athabasca Basin, Saskatchewan, the company in late August kicked off a Phase 3 diamond drill program to expand the footprint of mineralization, targeting the down-dip extents of the Gemini Mineralized Zone (GMZ).

proactiveinvestors.com 2024 Aug 28
ATHA Stock News Image - zacks.com

Here is how Athira Pharma, Inc. (ATHA) and HCA Healthcare (HCA) have performed compared to their sector so far this year.

zacks.com 2024 Aug 23
10 of 44